Healthpeak Properties (DOC) Projected to Announce Quarterly Earnings on Tuesday

Healthpeak Properties (NYSE:DOC) is projected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Healthpeak Properties to post earnings of $0.0282 per share and revenue of $725.6440 million for the quarter. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Parties may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 10:00 AM ET.

Healthpeak Properties (NYSE:DOC) last released its quarterly earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The business had revenue of $752.95 million for the quarter, compared to analysts’ expectations of $694.59 million. During the same quarter in the prior year, the firm posted $0.46 EPS. The company’s revenue was up 7.1% compared to the same quarter last year. On average, analysts expect Healthpeak Properties to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Healthpeak Properties Stock Performance

Shares of DOC stock opened at $21.83 on Monday. The stock has a fifty day moving average price of $21.01 and a 200 day moving average price of $18.66. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.96 and a current ratio of 2.96. The stock has a market cap of $15.05 billion, a PE ratio of 68.21, a P/E/G ratio of 3.39 and a beta of 1.01. Healthpeak Properties has a 1 year low of $15.70 and a 1 year high of $22.95.

Healthpeak Properties Announces Dividend

The company also recently declared a monthly dividend, which will be paid on Friday, September 25th. Stockholders of record on Monday, September 14th will be paid a dividend of $0.1017 per share. This represents a c) annualized dividend and a dividend yield of 5.6%. The ex-dividend date of this dividend is Monday, September 14th. Healthpeak Properties’s payout ratio is 381.25%.

Analysts Set New Price Targets

A number of brokerages recently commented on DOC. BMO Capital Markets increased their price objective on shares of Healthpeak Properties from $20.00 to $24.00 and gave the company an “outperform” rating in a research note on Monday, June 15th. Citigroup lifted their target price on shares of Healthpeak Properties from $17.50 to $20.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Wall Street Zen upgraded shares of Healthpeak Properties from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. UBS Group lifted their price objective on Healthpeak Properties from $19.00 to $21.50 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, Mizuho increased their target price on Healthpeak Properties from $21.00 to $24.00 and gave the company an “outperform” rating in a report on Monday, July 6th. Four equities research analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $20.62.

Insider Activity at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total value of $213,736.05. Following the completion of the sale, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. This represents a 59.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.23% of the company’s stock.

Institutional Investors Weigh In On Healthpeak Properties

Hedge funds have recently modified their holdings of the stock. State Street Corp grew its position in Healthpeak Properties by 1.8% in the third quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock valued at $947,889,000 after acquiring an additional 895,460 shares in the last quarter. Fuller & Thaler Asset Management Inc. boosted its stake in shares of Healthpeak Properties by 19.2% in the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock valued at $476,744,000 after purchasing an additional 4,776,056 shares during the period. Invesco Ltd. grew its holdings in Healthpeak Properties by 9.9% during the 4th quarter. Invesco Ltd. now owns 18,298,776 shares of the real estate investment trust’s stock valued at $294,244,000 after purchasing an additional 1,648,012 shares in the last quarter. Morgan Stanley increased its stake in Healthpeak Properties by 0.6% during the 4th quarter. Morgan Stanley now owns 12,251,344 shares of the real estate investment trust’s stock worth $197,002,000 after buying an additional 71,508 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in Healthpeak Properties by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 11,107,199 shares of the real estate investment trust’s stock worth $178,604,000 after buying an additional 523,818 shares in the last quarter. 93.57% of the stock is currently owned by hedge funds and other institutional investors.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.